See more : American Lithium Corp. (LI.V) Income Statement Analysis – Financial Results
Complete financial analysis of Editas Medicine, Inc. (EDIT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Editas Medicine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- EQRx, Inc. (EQRXW) Income Statement Analysis – Financial Results
- SITC International Holdings Company Limited (SITIF) Income Statement Analysis – Financial Results
- Amiyaki Tei Co., Ltd. (2753.T) Income Statement Analysis – Financial Results
- Karat Packaging Inc. (KRT) Income Statement Analysis – Financial Results
- Auscan Resources Inc. (AHELF) Income Statement Analysis – Financial Results
Editas Medicine, Inc. (EDIT)
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 78.12M | 19.71M | 25.54M | 90.73M | 20.53M | 31.94M | 13.73M | 6.05M | 1.63M | 0.00 | 0.00 |
| Cost of Revenue | 177.65M | 6.34M | 5.05M | 158.00M | 96.90M | 90.65M | 83.16M | 56.98M | 18.85M | 5.07M | 1.59M |
| Gross Profit | -99.53M | 13.38M | 20.49M | -67.26M | -76.37M | -58.72M | -69.43M | -50.93M | -17.22M | -5.07M | -1.59M |
| Gross Profit Ratio | -127.40% | 67.85% | 80.22% | -74.13% | -371.96% | -183.85% | -505.76% | -841.33% | -1,056.91% | 0.00% | 0.00% |
| Research & Development | 177.65M | 174.96M | 142.51M | 158.00M | 96.90M | 90.65M | 83.16M | 56.98M | 18.85M | 5.07M | 1.59M |
| General & Administrative | 69.65M | 70.70M | 76.18M | 67.58M | 64.56M | 55.01M | 50.50M | 46.26M | 18.10M | 7.65M | 3.63M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.65M | 70.70M | 76.18M | 67.58M | 64.56M | 55.01M | 50.50M | 46.26M | 18.10M | 7.65M | 3.63M |
| Other Expenses | 0.00 | 1.29M | -1.70M | 16.26M | -137.00K | 328.00K | 587.00K | -57.00K | -37.45M | -928.00K | 0.00 |
| Operating Expenses | 247.30M | 245.66M | 218.69M | 225.57M | 161.45M | 145.66M | 133.66M | 103.24M | 36.94M | 12.72M | 3.68M |
| Cost & Expenses | 247.30M | 245.66M | 218.69M | 225.57M | 161.45M | 145.66M | 133.66M | 103.24M | 36.94M | 12.72M | 5.27M |
| Interest Income | 17.57M | 4.23M | 2.34M | 2.61M | 7.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.23M | 0.00 | 0.00 | 0.00 | 0.00 | 978.00K | 0.00 | 143.00K | 34.00K | 0.00 |
| Depreciation & Amortization | 6.06M | 6.34M | 5.05M | 3.96M | 2.83M | 3.25M | 2.68M | 1.20M | 471.00K | 157.00K | 3.00K |
| EBITDA | -163.12M | -219.61M | -188.09M | -130.88M | -138.09M | -110.47M | -116.66M | -96.07M | -72.29M | -13.49M | -5.22M |
| EBITDA Ratio | -208.80% | -1,146.26% | -756.13% | -148.61% | -687.05% | -355.07% | -869.36% | -1,606.56% | -4,466.36% | 0.00% | 0.00% |
| Operating Income | -169.18M | -225.95M | -193.15M | -134.84M | -140.92M | -113.73M | -119.93M | -97.19M | -35.31M | -12.72M | -5.22M |
| Operating Income Ratio | -216.56% | -1,146.26% | -756.13% | -148.61% | -686.39% | -356.10% | -873.64% | -1,605.62% | -2,167.71% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.96M | 5.52M | 644.00K | 18.86M | 7.18M | 3.77M | -391.00K | 5.00K | -37.59M | -962.00K | -54.00K |
| Income Before Tax | -153.22M | -220.43M | -192.50M | -115.98M | -133.75M | -109.95M | -120.32M | -97.18M | -72.90M | -13.69M | -5.27M |
| Income Before Tax Ratio | -196.13% | -1,118.26% | -753.61% | -127.82% | -651.43% | -344.28% | -876.49% | -1,605.53% | -4,475.14% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -16.08M | -7.40M | -6.56M | -10.28M | -3.12M | -1.12M | -1.32M | -37.77M | -894.00K | 75.00K |
| Net Income | -153.22M | -204.35M | -185.11M | -109.41M | -123.47M | -109.95M | -120.32M | -97.18M | -72.90M | -13.69M | -5.35M |
| Net Income Ratio | -196.13% | -1,036.69% | -724.66% | -120.59% | -601.36% | -344.28% | -876.49% | -1,605.53% | -4,475.14% | 0.00% | 0.00% |
| EPS | -2.02 | -2.98 | -2.74 | -1.87 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -0.89 | -17.80 |
| EPS Diluted | -2.02 | -2.98 | -2.74 | -1.87 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -0.89 | -17.80 |
| Weighted Avg Shares Out | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.10M | 40.32M | 32.22M | 35.70M | 15.44M | 300.48K |
| Weighted Avg Shares Out (Dil) | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.10M | 40.32M | 32.22M | 35.70M | 15.44M | 300.48K |
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)
Editas Medicine: A Risk/Reward Worth Considering
Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)
Buy These 3 Small-Cap Stocks for 90% to 301% Returns
Source: https://incomestatements.info
Category: Stock Reports